Search

Your search keyword '"Non-small cell lung cancer -- Genetic aspects -- Drug therapy"' showing total 68 results
Start Over Descriptor "Non-small cell lung cancer -- Genetic aspects -- Drug therapy"
68 results on '"Non-small cell lung cancer -- Genetic aspects -- Drug therapy"'

1. Successful treatment of epidermal growth factor receptor exon 19 deletion non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: A case report

Author

Li, Zhichao, Wang, Gang, Xue, Guoliang, Wang, Nan, Hu, Yanting, Cao, Pikun, Cai, Hongchao, Wei, Zhigang, and Ye, Xin

Subjects
Drug therapy, Diagnosis, Complications and side effects, Genetic aspects, Dosage and administration, Causes of, Health aspects, ErbB receptors -- Health aspects, Osimertinib -- Dosage and administration -- Complications and side effects, Interstitial lung diseases -- Diagnosis -- Causes of -- Drug therapy, Kinase inhibitors -- Dosage and administration -- Complications and side effects, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Lung diseases, Interstitial -- Diagnosis -- Causes of -- Drug therapy, Lung cancer, Non-small cell -- Genetic aspects -- Drug therapy
Abstract

Author(s): Zhichao Li [1]; Gang Wang [1]; Guoliang Xue [1]; Nan Wang [1]; Yanting Hu [1]; Pikun Cao [1]; Hongchao Cai [1]; Zhigang Wei (corresponding author) [1]; Xin Ye (corresponding [...], Osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), has revolutionized one of the standard most efficient treatments for EGFR mutation-positive non-small cell lung cancer (NSCLC). Osimertinib, a third-generation EGFR-TKI, is currently one of most efficient treatments in clinical practice. However, it has a potentially fatal side effect: interstitial lung disease (ILD). When severe ILD occurs, a drug substitution is often required, and there is a rising concern about which drug to choose to inhibit the progression of NSCLC and avoid aggravating while alleviating ILD. Herein, we report an NSCLC case with osimertinib-induced ILD successfully rechallenged by almonertinib. In addition, we conducted a literature review on the clinical efficacy and adverse effects of almonertinib, hoping to provide insight into NSCLC treatment. Keywords: Almonertinib, interstitial lung disease, non-small cell lung cancer, osimertinib

Published
2024
Full Text
View/download PDF

2. Inhibitor of KRAS gene mutation shows promise in lung, bowel and other solid tumors

Subjects
Genetic research -- Health aspects -- Genetic aspects, Cetuximab -- Health aspects, Cancer -- Genetic aspects -- Drug therapy, Women's health -- Health aspects, Genes -- Genetic aspects -- Health aspects, Afatinib -- Health aspects, Gene mutation -- Genetic aspects -- Health aspects, Tumors -- Drug therapy -- Genetic aspects, Colorectal cancer -- Genetic aspects -- Drug therapy, Pembrolizumab -- Health aspects, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Health, Women's issues/gender studies
Abstract

2020 NOV 12 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- New results from early clinical trials of a drug that targets a cancer-causing mutation [...]

Published
2020

3. Researchers at Sungkyunkwan University School of Medicine Target Non-Small Cell Lung Cancer (Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: Are They Different from Those with Common EGFR ...)

Subjects
Cancer treatment, Physical fitness, Cancer research -- Genetic aspects, Afatinib, Biochemistry -- Genetic aspects, Small cell lung cancer -- Genetic aspects -- Drug therapy, Epidermal growth factors -- Genetic aspects, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Cancer metastasis -- Genetic aspects -- Drug therapy, Health
Abstract

2020 OCT 24 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- A new study on Oncology - Non-Small Cell Lung Cancer is now [...]

Published
2020

4. Researchers at All India Institute of Medical Sciences (AIIMS) Report Findings in Small Cell Lung Cancer (Spectrum of uncommon and compound epidermal growth factor receptor mutations in non-small-cell lung carcinomas with treatment response and ...)

Subjects
Cancer treatment -- Reports, Physical fitness -- Reports, Tyrosine -- Reports -- Genetic aspects, Biochemistry -- Genetic aspects -- Reports, Small cell lung cancer -- Genetic aspects -- Drug therapy, Epidermal growth factors -- Reports -- Genetic aspects, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Health
Abstract

2020 OCT 10 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators discuss new findings in Oncology - Small Cell Lung Cancer. According [...]

Published
2020

5. Data on Oncology Discussed by Researchers at Rabin Medical Center (Tyrosine Kinase Inhibitors as a Treatment of Symptomatic CNS Metastases in Oncogene-Driven NSCLC)

Subjects
Physical fitness, Medical centers, Tyrosine -- Genetic aspects, Radiotherapy, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Phenols (Class of compounds), Cancer metastasis -- Genetic aspects -- Drug therapy, Health
Abstract

2020 OCT 3 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Researchers detail new data in oncology. According to news reporting originating from [...]

Published
2020

6. Data on Lung Cancer Reported by Researchers at National Clinical Research Center for Cancer (Response to tyrosine kinase inhibitors in lung adenocarcinoma with the rare epidermal growth factor receptor mutation S768I and G724S: A case report ...)

Subjects
Physical fitness, Osimertinib, Cancer research -- Genetic aspects, Tyrosine -- Genetic aspects, Afatinib, Epidermal growth factors -- Genetic aspects, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Phenols (Class of compounds), Health
Abstract

2020 SEP 26 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Research findings on lung cancer are discussed in a new report. According [...]

Published
2020

7. Studies from University Hospital Virgen Macarena Describe New Findings in Non-Small Cell Lung Cancer (ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small ...)

Subjects
AstraZeneca PLC, Physical fitness, Osimertinib, Cancer research -- Genetic aspects, Small cell lung cancer -- Genetic aspects -- Drug therapy, Epidermal growth factors -- Genetic aspects, Pharmaceutical industry, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Health
Abstract

2020 JUL 25 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Researchers detail new data in Oncology - Non-Small Cell Lung Cancer. According [...]

Published
2020

8. Study Results from Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital in the Area of Non-Small Cell Lung Cancer Reported (Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer)

Subjects
Physical fitness, Osimertinib, Cancer research, Small cell lung cancer -- Genetic aspects -- Drug therapy, Epidermal growth factors, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Tyrosine, Phenols (Class of compounds), Editors, Lung cancer, Health
Abstract

2020 FEB 1 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Fresh data on Oncology - Non-Small Cell Lung Cancer are presented in [...]

Published
2020

9. Investigators at Erasmus MC Cancer Institute Zero in on Personalized Medicine (Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer)

Subjects
Precision medicine, Physical fitness, Cancer genetics -- Genetic aspects -- Drug therapy, Crizotinib, DNA, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, RNA, Drugs, Editors, Lung cancer, Health
Abstract

2020 JAN 4 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Researchers detail new data in Drugs and Therapies - Personalized Medicine. According [...]

Published
2020

10. Studies from Laboratory of Molecular Biology Provide New Data on Cancer Research (BRAF Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale)

Subjects
United States. Food and Drug Administration, Clinical trials, Molecular biology, Physical fitness, Dabrafenib, Cancer -- Genetic aspects -- Drug therapy, Cancer research, Gene mutation, Trametinib, Cancer patients -- Drug therapy, Drug approval, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Obesity, Editors, Lung cancer, Health, Laboratory of Molecular Biology
Abstract

2019 OCT 5 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Researchers detail new data in Oncology - Cancer Research. According to news [...]

Published
2019

11. New Non-Small Cell Lung Cancer Study Findings Recently Were Reported by Researchers at Institute for Cancer Research and Treatment (IRCCS) [The Presence of Concomitant Mutations Affects the Activity of Egfr Tyrosine Kinase Inhibitors In ...]

Subjects
Cancer treatment, Physical fitness, Cancer research, Tyrosine, Biochemistry, Small cell lung cancer -- Genetic aspects -- Drug therapy, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Phenols (Class of compounds), Amino acids, Anopheles, Obesity, Editors, Lung cancer, Health
Abstract

2019 JUN 22 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Researchers detail new data in Oncology - Non-Small Cell Lung Cancer. According [...]

Published
2019

12. Researchers from Sichuan Academy of Medical Sciences Detail New Studies and Findings in the Area of Non-Small Cell Lung Cancer (Effect of Egfr Gene Polymorphism On Efficacy of Chemotherapy Combined With Targeted Therapy for Non-small Cell Lung ...)

Subjects
Chemotherapy -- Patient outcomes, Genetic polymorphisms -- Health aspects, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Small cell lung cancer, Cancer research, Anopheles, Cancer genetics, Physical fitness, Obesity, Technology, Cancer metastasis, Editors, Lung cancer, Health
Abstract

2019 MAY 11 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Oncology - Non-Small Cell Lung Cancer have been [...]

Published
2019

13. Findings from Affiliated Hospital Update Understanding of Lung Cancer (Combined Treatment of Abt199 and Irinotecan Suppresses Kras-mutant Lung Cancer Cells)

Subjects
Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Gene mutation -- Research, Irinotecan -- Dosage and administration, Obesity, Cancer research, Cancer treatment, Physical fitness, Lung cancer, Tumors, Cancer cells, Antineoplastic agents, Anopheles, Technology, Editors, Genetic research, Health
Abstract

2019 MAR 16 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Oncology - Lung Cancer have been published. According [...]

Published
2019

14. Pfizer gets positive opinion from EMA committee for Vizimpro to treat NSCLC with EGFR-activating mutations

Subjects
United States. Food and Drug Administration, Pfizer Inc., Pharmaceutical industry, Epidermal growth factors, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Cancer metastasis -- Genetic aspects -- Drug therapy, Cancer, Lung cancer, Marketing, Small cell lung cancer, Pharmaceuticals and cosmetics industries, European Union, European Union. European Commission, Vizimpro (Medication)
Abstract

Pfizer announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending Vizimpro (dacomitinib) 45 mg, as monotherapy, [...]

Published
2019

15. Mirati Therapeutics gets US FDA approval to begin phase 1/2 trial of KRAS G12C Inhibitor, MRTX849

Subjects
United States. Food and Drug Administration, Cancer treatment, Drug approval, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Colorectal cancer -- Genetic aspects -- Drug therapy, Cancer, Pharmaceutical industry, Lung cancer, Motor vehicle drivers, Tumors, Small cell lung cancer, Pharmaceuticals and cosmetics industries
Abstract

Mirati Therapeutics, Inc, a clinical stage targeted oncology company, announced that the US Food and Drug Administration (FDA) has cleared the company's investigational new drug (IND) application for MRTX849, a [...]

Published
2018

16. Investigators at Okayama University Hospital Zero in on Kinase Inhibitors (Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer)

Subjects
Physical fitness, Epidermal growth factors, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Health
Abstract

2018 AUG 11 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Data detailed on Drugs and Therapies - Kinase Inhibitors have been presented. [...]

Published
2018

17. Study Data from G. Mountzios and Co-Authors Update Knowledge of Lung Cancer (The emerging treatment landscape of advanced non-small cell lung cancer)

Subjects
Physical fitness, Cancer genetics -- Genetic aspects -- Drug therapy, Cancer research, Small cell lung cancer -- Genetic aspects -- Drug therapy, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Health
Abstract

2018 MAY 26 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Oncology - Lung Cancer have been published. According [...]

Published
2018

18. Boehringer Ingelheim receives US FDA approval for Gilotrif to treat patients with EGFR mutation-positive NSCLC

Subjects
United States. Food and Drug Administration, Boehringer Ingelheim Pharmaceuticals Inc., Epidermal growth factors, Pharmaceutical industry, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Pharmaceuticals and cosmetics industries, Gilotrif (Medication)
Abstract

Boehringer Ingelheim announced that the US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Gilotrif (afatinib) for the first-line treatment of patients with metastatic [...]

Published
2018

19. United States : Janssen Submits Application to U.S. FDA Seeking Approval of Amivantamab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Subjects
United States. Food and Drug Administration, Johnson & Johnson, Chemotherapy, Small cell lung cancer -- Genetic aspects -- Drug therapy, Epidermal growth factors -- Genetic aspects, Pharmaceutical industry, Drug approval, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Cancer metastasis -- Genetic aspects -- Drug therapy, Business, international
Abstract

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of amivantamab for [...]

Published
2020

20. Amgen's Sotorasib Granted Breakthrough Therapy Designation For Advanced Or Metastatic Non-Small Cell Lung Cancer Patients With KRAS G12C Mutation

Subjects
United States. Food and Drug Administration, Small cell lung cancer -- Genetic aspects -- Drug therapy, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Cancer metastasis -- Genetic aspects -- Drug therapy, General interest, News, opinion and commentary
Abstract

THOUSAND OAKS: Amgen has issued the following news release: Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for its investigational KRASG12C [...]

Published
2020

21. Amgen's Sotorasib Granted Breakthrough Therapy Designation For Advanced Or Metastatic Non-Small Cell Lung Cancer Patients With KRAS G12C Mutation

Subjects
United States. Food and Drug Administration, Small cell lung cancer -- Genetic aspects -- Drug therapy, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Cancer metastasis -- Genetic aspects -- Drug therapy, Business, international, Law
Abstract

Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for its investigational KRASG12C inhibitor, sotorasib, for the treatment of patients with locally [...]

Published
2020

22. Janssen Submits Application to U.S. FDA Seeking Approval of Amivantamab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Subjects
United States. Food and Drug Administration, Johnson & Johnson, Small cell lung cancer -- Genetic aspects -- Drug therapy, Epidermal growth factors -- Genetic aspects, Pharmaceutical industry, Drug approval, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Cancer metastasis -- Genetic aspects -- Drug therapy, General interest, News, opinion and commentary
Abstract

New Brunswick, New Jersey: Johnson & Johnson has issued the following press release: The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a Biologics License Application [...]

Published
2020

23. Janssen Submits Application to U.S. FDA Seeking Approval of Amivantamab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Subjects
United States. Food and Drug Administration, Johnson & Johnson, Osimertinib, Chemotherapy, Small cell lung cancer -- Genetic aspects -- Drug therapy, Epidermal growth factors -- Genetic aspects, Pharmaceutical industry, Drug approval, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Cancer metastasis -- Genetic aspects -- Drug therapy, Business, Business, international
Abstract

Expanded Access Program Established for Patients in the U.S. Who May Benefit from Investigational Therapy While Application is Under Review RARITAN, N.J. -- The Janssen Pharmaceutical Companies of Johnson & [...]

Published
2020

24. Inhibitor of KRAS gene mutation shows promise in lung, bowel and other solid tumors

Subjects
Genetic research -- Health aspects -- Genetic aspects, Cetuximab -- Health aspects, Genes -- Genetic aspects -- Health aspects, Afatinib -- Health aspects, Gene mutation -- Genetic aspects -- Health aspects, Colorectal cancer -- Genetic aspects -- Drug therapy, Pembrolizumab -- Health aspects, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Ovarian cancer -- Drug therapy -- Genetic aspects, Business, international, Law
Abstract

New results from early clinical trials of a drug that targets a cancer-causing mutation in the KRAS gene have shown that it can shrink tumours and is well-tolerated by patients. [...]

Published
2020

25. Guardant companion diagnostic gets FDA nod as 1st liquid biopsy with NGS

Subjects
AstraZeneca PLC, Respiratory system agents, Pharmaceutical industry, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Business, international, Law, Tagrisso (Medication)
Abstract

FDA Friday approved Guardant Health's liquid biopsy diagnostic that uses next-generation sequencing (NGS) to identify patients with mutations of the epidermal growth factor receptor (EGFR) gene in metastatic non-small cell [...]

Published
2020

26. Findings from H. Niu and Co-Authors Broaden Understanding of Small Cell Lung Cancer (Treatment of Leptomeningeal Metastases in a Patient with Non-Small Cell Lung Cancer Harboring EGFR T790M Mutation)

Subjects
Cancer treatment, Physical fitness, Small cell lung cancer -- Genetic aspects -- Drug therapy, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Cancer metastasis -- Genetic aspects -- Drug therapy, Health
Abstract

2017 NOV 11 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- New research on Oncology - Small Cell Lung Cancer is the subject [...]

Published
2017

27. New Molecular Research Findings Reported from Sichuan University (L1198F Mutation Resensitizes Crizotinib to ALK by Altering the Conformation of Inhibitor and ATP Binding Sites)

Subjects
United States. Food and Drug Administration, Physical fitness, Drug approval, Lymphomas -- Genetic aspects -- Drug therapy, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Health
Abstract

2017 APR 15 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Molecular Research have been published. According to news [...]

Published
2017

28. Researchers at Hubei University of Medicine Target Small Cell Lung Cancer (Circulating cell-free DNA has a high degree of specificity to detect exon 19 deletions and the single-point substitution mutation L858R in non-small cell lung cancer)

Subjects
Physical fitness, Cancer genetics -- Genetic aspects -- Drug therapy, Genetic research, Cancer research, Biochemistry, DNA, Small cell lung cancer -- Genetic aspects -- Drug therapy, Epidermal growth factors, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Health
Abstract

2017 MAR 25 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Fresh data on Oncology - Small Cell Lung Cancer are presented in [...]

Published
2017

29. Researchers at Massachusetts General Hospital Have Reported New Data on Lung Cancer (Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer)

Subjects
Physical fitness, Cancer genetics -- Genetic aspects -- Drug therapy, Cancer research, Tyrosine, Radiotherapy, Lymphomas -- Genetic aspects -- Drug therapy, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Phenols (Class of compounds), Radiation (Physics), Health, Massachusetts General Hospital
Abstract

2016 OCT 22 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Fresh data on Oncology - Lung Cancer are presented in a new [...]

Published
2016

30. Research Results from Institute for Cancer Research and Treatment (IRCCS) Update Knowledge of Science [Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR)]

Subjects
Physical fitness, Cancer -- Genetic aspects -- Drug therapy, Cancer research, Gene mutation, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, RNA, Health
Abstract

2016 OCT 22 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- A new study on Science is now available. According to news reporting [...]

Published
2016

31. Data from Harvard School of Medicine Advance Knowledge in Lung Cancer (Radiomic phenotype features predict pathological response in non-small cell lung cancer)

Subjects
Physical fitness, Small cell lung cancer -- Genetic aspects -- Drug therapy, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Health
Abstract

2016 SEP 10 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- A new study on Oncology - Lung Cancer is now available. According [...]

Published
2016

32. QIAGEN builds on global collaboration with Amgen

Subjects
Vice presidents (Organizations), Drug approval, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Small cell lung cancer, Cancer treatment, Cancer, Lung cancer, Cancer patients, Biotechnology industry
Abstract

QIAGEN to pursue global regulatory approvals, including premarket approval from FDA QIAGEN has announced a strategic collaboration to develop tissue-based companion diagnostics for Amgen's investigational cancer treatment AMG 510 to [...]

Published
2020

33. United States : FDA Approves Genentechs Rozlytrek (entrectinib) for People With ROS1-Positive, Metastatic Non-Small Cell Lung Cancer and NTRK Gene Fusion-Positive Solid Tumors

Subjects
United States. Food and Drug Administration, Cancer genetics -- Genetic aspects -- Drug therapy, Genes, Small cell lung cancer -- Genetic aspects -- Drug therapy, Drug approval, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Cancer metastasis -- Genetic aspects -- Drug therapy, Phenols (Class of compounds), Tumors, Pediatrics, Morbidity, Tyrosine, Biological products industry, Child health, Lung cancer, Business, international
Abstract

Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) has approved Rozlytrek (entrectinib) for the treatment of adults with ROS1-positive, metastatic non-small cell [...]

Published
2019

34. Switzerland : FDA approves Roches Rozlytrek (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours

Subjects
United States. Food and Drug Administration, Cancer genetics -- Genetic aspects -- Drug therapy, Genes, Small cell lung cancer -- Genetic aspects -- Drug therapy, Drug approval, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Cancer metastasis -- Genetic aspects -- Drug therapy, Morbidity, Tyrosine, Phenols (Class of compounds), Tumors, Pediatrics, Lung cancer, Business, international
Abstract

Roche announced that the US Food and Drug Administration (FDA) has approved Rozlytrek (entrectinib) for the treatment of adults with ROS1-positive, metastatic non-small cell lung cancer (NSCLC). The FDA has [...]

Published
2019

35. FDA approves Roche's Rozlytrek (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours

Subjects
United States. Food and Drug Administration, Roche Holding AG, Cancer genetics -- Genetic aspects -- Drug therapy, Genes, Biotechnology industries, Small cell lung cancer -- Genetic aspects -- Drug therapy, Drug approval, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Cancer metastasis -- Genetic aspects -- Drug therapy, Morbidity, Tyrosine, Phenols (Class of compounds), Tumors, Pediatrics, Lung cancer, General interest, News, opinion and commentary
Abstract

Basel: Roche Holding AG has issued the following press release: Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Rozlytrek (entrectinib) [...]

Published
2019

36. FDA approves Roche's RozlytrekTM (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours

Subjects
United States. Food and Drug Administration, Cancer genetics -- Genetic aspects -- Drug therapy, Genes, Small cell lung cancer -- Genetic aspects -- Drug therapy, Drug approval, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Cancer metastasis -- Genetic aspects -- Drug therapy, Morbidity, Tyrosine, Phenols (Class of compounds), Tumors, Pediatrics, Lung cancer, General interest, News, opinion and commentary
Abstract

Zurich, Switzerland: SIX Swiss Exchange Ltd has issued the following notice: Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Rozlytrek [...]

Published
2019

37. FDA Approves Genentech's Rozlytrek (entrectinib) for People With ROS1-Positive, Metastatic Non-Small Cell Lung Cancer and NTRK Gene Fusion-Positive Solid Tumors

Subjects
United States. Food and Drug Administration, Cancer genetics -- Genetic aspects -- Drug therapy, Genes, Small cell lung cancer -- Genetic aspects -- Drug therapy, Drug approval, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Cancer metastasis -- Genetic aspects -- Drug therapy, Biological products industry, Phenols (Class of compounds), Tumors, Pediatrics, Biotechnology industries, Tyrosine, Child health, Lung cancer, General interest, News, opinion and commentary
Abstract

SOUTH SAN FRANCISCO: Genentech has issued the following press release: Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug [...]

Published
2019

38. Correction - FDA approves Roche's Rozlytrek (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours

Subjects
United States. Food and Drug Administration, Roche Holding AG, Genes, Biotechnology industries, Small cell lung cancer -- Genetic aspects -- Drug therapy, Drug approval, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Cancer metastasis -- Genetic aspects -- Drug therapy, Tumors, Business, Business, international
Abstract

M2 PRESSWIRE-August 16, 2019-: Correction - FDA approves Roche's Rozlytrek (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours (C)1994-2019 M2 COMMUNICATIONS RDATE:16082019 [...]

Published
2019

39. FDA approves Roche's RozlytrekTM (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours

Subjects
United States. Food and Drug Administration, Roche Holding AG, Cancer genetics -- Genetic aspects -- Drug therapy, Genes, Biotechnology industries, Small cell lung cancer -- Genetic aspects -- Drug therapy, Drug approval, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Cancer metastasis -- Genetic aspects -- Drug therapy, Tumors, Lung cancer, Business, Business, international
Abstract

M2 PRESSWIRE-August 16, 2019-: FDA approves Roche's RozlytrekTM (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours (C)1994-2019 M2 COMMUNICATIONS RDATE:16082019 - First [...]

Published
2019

40. FDA approves Roche's RozlytrekTM (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours

Subjects
United States. Food and Drug Administration, Roche Holding AG, Cancer genetics -- Genetic aspects -- Drug therapy, Biotechnology industries, Small cell lung cancer -- Genetic aspects -- Drug therapy, Drug approval, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Cancer metastasis -- Genetic aspects -- Drug therapy, Tumors, Pediatrics, Lung cancer, Business, international
Abstract

(GLOBE NEWSWIRE via COMTEX) -- - First FDA-approved treatment designed to target both ROS1 and NTRK that also shows response in cancer that has spread to the brain - Roche's [...]

Published
2019

41. Pfizer Receives Positive CHMP Opinion for Vizimpro[R] (dacomitinib) for the First-line Treatment of Adult Patients with Locally Advanced Or Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mutations

Subjects
United States. Food and Drug Administration, Pfizer Inc., Pharmaceutical industry, Epidermal growth factors, Small cell lung cancer -- Genetic aspects -- Drug therapy, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Cancer metastasis -- Genetic aspects -- Drug therapy, Backup software, Lung cancer, Marketing, Business, Business, international, European Union, European Union. European Commission, Vizimpro (Medication)
Abstract

NEW YORK -- Pfizer today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending Vizimpro[R] (dacomitinib) [...]

Published
2019

42. Janssen Submits Application to U.S. FDA Seeking Approval of Amivantamab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Subjects
United States. Food and Drug Administration, Johnson & Johnson, Cancer treatment, Cancer -- Genetic aspects -- Drug therapy, Small cell lung cancer -- Genetic aspects -- Drug therapy, Epidermal growth factors -- Genetic aspects, Pharmaceutical industry, Drug approval, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Cancer metastasis -- Genetic aspects -- Drug therapy, Government, Political science
Abstract

2020 DEC 17 (VerticalNews) -- By a News Reporter-Staff News Editor at Politics & Government Week -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a [...]

Published
2020

43. Researchers from Shandong Cancer Hospital and Institute Discuss Findings in Non-Small Cell Lung Cancer (Perspective On Treatment for Unresectable Locally Advanced Non-small Cell Lung Cancer With Oncogene-driven Mutation: a Narrative Review)

Subjects
Cancer treatment, Cancer genetics -- Genetic aspects -- Drug therapy, Cancer research -- Genetic aspects, Biochemistry -- Genetic aspects, Journalistic ethics, Small cell lung cancer -- Genetic aspects -- Drug therapy, Immunotherapy, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Health
Abstract

2020 NOV 25 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Current study results on Oncology - Non-Small Cell Lung Cancer have been published. According to [...]

Published
2020

44. Researchers at Sungkyunkwan University School of Medicine Target Lung Cancer (Immune checkpoint inhibitors in driver mutation-positive nonsmall cell lung cancer: is there a role?)

Subjects
Bevacizumab, Cancer research -- Genetic aspects, Respiratory system agents, Immunotherapy, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Health
Abstract

2020 NOV 25 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Fresh data on Oncology - Lung Cancer are presented in a new report. According to [...]

Published
2020

45. Study Data from Kindai University Faculty of Medicine Update Knowledge of Lung Cancer (Clinical impacts of EGFR mutation status: analysis of 5,780 surgically resected lung cancer cases)

Subjects
Cancer research -- Genetic aspects, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Health
Abstract

2020 JUL 17 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Researchers detail new data in Oncology - Lung Cancer. According to news reporting [...]

Published
2020

46. Fondazione Policlinico Universitario Agostino Gemelli IRCCS Researchers Provide New Data on Non-Small Cell Lung Cancer (Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives)

Subjects
Cancer genetics -- Genetic aspects -- Drug therapy, Osimertinib -- Reports, Substance abuse treatment -- Reports, Cancer research -- Reports -- Genetic aspects, Chemotherapy -- Reports, Biochemistry -- Genetic aspects -- Reports, Small cell lung cancer -- Genetic aspects -- Drug therapy, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Alectinib -- Reports, Anopheles, Phenols (Class of compounds), Tumors, Tyrosine, Molecular biology, Editors, Lung cancer, Business, Health, Health care industry
Abstract

2020 MAY 26 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- New study results on non-small cell lung cancer have been published. According to news originating [...]

Published
2020

47. Investigators at Nagoya University Graduate School of Medicine Target Lung Cancer (Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer Patients With EGFR Mutation)

Subjects
Pfizer Inc., Eli Lilly Japan KK, AstraZeneca PLC, Bevacizumab, Chemotherapy, Respiratory system agents, Vascular endothelial growth factor, Carboplatin, Immunotherapy, Pharmaceutical industry, Pemetrexed, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Cancer treatment, Angiogenesis inhibitors, Anopheles, Antineoplastic agents, Endothelial growth factors, Finance, Tumors, Endothelium, Japanese history, 1868-1912 (Meiji period), Retirement benefits, Editors, Lung cancer, Health
Abstract

2020 MAR 11 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Current study results on Oncology - Lung Cancer have been published. According to news reporting [...]

Published
2020

48. Foundation Medicine Publishes New Data in Nature Medicine Supporting Blood Tumor Mutational Burden (bTMB) as a Novel Predictor of Response to Cancer Immunotherapy

Subjects
United States. Food and Drug Administration, Roche Holding AG, Cancer -- Genetic aspects -- Drug therapy, Cancer research, Biotechnology industries, Immunotherapy, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Hematoma -- Genetic aspects -- Drug therapy, General interest, News, opinion and commentary
Abstract

CAMBRIDGE: Foundation Medicine, has issued the following news release: Foundation Medicine, today announced the publication of the results of a large study demonstrating that its novel, investigational assay to measure [...]

Published
2018

49. Foundation Medicine Publishes New Data in Nature Medicine Supporting Blood Tumor Mutational Burden (bTMB) as a Novel Predictor of Response to Cancer Immunotherapy

Subjects
United States. Food and Drug Administration, Roche Holding AG, Cancer -- Genetic aspects -- Drug therapy, Cancer research, Biotechnology industries, Immunotherapy, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Hematoma -- Genetic aspects -- Drug therapy, Business, Business, international
Abstract

-- New publication details Foundation Medicine's assay's ability to measure bTMB and to identify patients who may benefit from anti-PD-L1 therapy -- CAMBRIDGE, Mass. -- Foundation Medicine, today announced the [...]

Published
2018

50. Blueprint Medicines Publication in Cancer Discovery Highlights Preclinical and Clinical Proof-of-Concept Data for Highly Selective RET Inhibitor BLU-667

Subjects
Thyroid cancer -- Genetic aspects -- Drug therapy, Drugs, Electronic periodicals, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, General interest, News, opinion and commentary, American Association for Cancer Research
Abstract

CAMBRIDGE: Blueprint Medicines has issued the following news release: Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today [...]

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results